Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.
Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.
Recalling Firm: Breckenridge Pharmaceutical, Inc.
Grund für den Rückruf / Gefahr
TranslatedCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Produktbeschreibung & Identifikation
TranslatedDuloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.
Additional Source Details
| Field | Value |
|---|---|
| City | Berkeley Heights |
| State | NJ |
| Openfda › Unii | 9044SC542W |
| Openfda › Route | ORAL |
| Openfda › Rxcui › 1 | 596926 |
| Openfda › Rxcui › 2 | 596930 |
| Openfda › Rxcui › 3 | 596934 |
| Openfda › Rxcui › 4 | 616402 |
| Openfda › Spl id | 32327581-bdab-41ac-9adc-bf208e1c4e42 |
| Openfda › Brand name | DULOXETINE |
| Openfda › Spl set id | caef6f50-1571-4ec7-8f8c-42b924d323ee |
| Openfda › Package ndc › 1 | 51991-746-06 |
| Openfda › Package ndc › 2 | 51991-746-90 |
| Openfda › Package ndc › 3 | 51991-746-05 |
| Openfda › Package ndc › 4 | 51991-747-33 |
| Openfda › Package ndc › 5 | 51991-747-90 |
| Openfda › Package ndc › 6 | 51991-747-10 |
| Openfda › Package ndc › 7 | 51991-748-33 |
| Openfda › Package ndc › 8 | 51991-748-90 |
| Openfda › Package ndc › 9 | 51991-748-10 |
| Openfda › Package ndc › 10 | 51991-750-33 |
| Openfda › Package ndc › 11 | 51991-750-90 |
| Openfda › Package ndc › 12 | 51991-750-05 |
| Openfda › Package ndc › 13 | 51991-750-10 |
| Openfda › Product ndc › 1 | 51991-746 |
| Openfda › Product ndc › 2 | 51991-747 |
| Openfda › Product ndc › 3 | 51991-748 |
| Openfda › Product ndc › 4 | 51991-750 |
| Openfda › Generic name | DULOXETINE HYDROCHLORIDE |
| Openfda › Product type | HUMAN PRESCRIPTION DRUG |
| Openfda › Substance name | DULOXETINE HYDROCHLORIDE |
| Openfda › Manufacturer name | Breckenridge Pharmaceutical, Inc. |
| Openfda › Application number | ANDA203088 |
| Openfda › Is original packager | true |
| Event id | 99108 |
| Address 1 | 200 Connell Dr Ste 4200 |
| Address 2 | N/A |
| Code info | Lot: a) 241074C, Exp. Date May 2027; 240317, 240318, 240315C, 240373C, 240370C, 240375C, 240413C, Exp. Date February 2027; 240316,Exp. Date January 2027; 232311, Exp. Date November 2026; b) 240978C, 241052C, Exp. Date April 2027. |
| Postal code | 07922-2805 |
| Report date | 20260617 |
| Product type | Drugs |
| Product quantity | 359,676 bottles |
| Reason for recall | CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit |
| Voluntary mandated | Voluntary: Firm initiated |
| Recall initiation date | 20260604 |
| Initial firm notification | Letter |
| Center classification date | 20260608 |
Consumer Action Protocol: What You Should Do Immediately
Safety StepsInspect the NDC code, batch number, or control number on your medicine bottle or blister packaging to confirm whether your unit is included.
Do not abruptly stop critical prescribed medication without physician advice. Contact your dispensing pharmacist immediately for a safe alternative.
Under statutory consumer protection rules, consumers are entitled to a full refund, certified replacement, or free repair kit without needing the original sales receipt.
If you suffered an injury, illness, or property damage from this product, file an official incident report with regulatory authorities (FDA Drugs).
Your Legal Rights as a Consumer
Recalls are legally binding corrective safety actions overseen by statutory government bodies. Recalling entities are legally prohibited from charging consumers for official safety remedies. If a retailer or dealership refuses your recall remedy, notify the issuing regulatory agency immediately.
Frequently Asked Questions About This Recall
FAQ GuideQ1:What should I do immediately if I own or bought Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (5199...?
Check the lot number and NDC on your prescription label. For essential medications, consult your doctor or dispensing pharmacist immediately before abruptly stopping your dose.
Q2:Can I get a full refund or free repair for this recall?
Yes. Recalling manufacturers and retail merchants are required under consumer protection regulations to offer a statutory remedy—typically a full refund, certified repair kit, or replacement unit.
Q3:Do I need my original sales receipt to claim a remedy or refund?
In most recall cases, no receipt is required. Because safety recalls are matters of public health and statutory compliance, retailers and manufacturers routinely issue refunds, store credit, or replacement kits upon presentation of the affected product or lot code.
Q4:Where can I verify official information for this safety alert?
This safety alert is aggregated directly from official regulatory agency records (FDA Drugs). You can click the 'Official Agency Alert' link on this page to view the primary government notice and contact the manufacturer directly.
Prüfen Sie weitere Produkte in Ihrem Haushalt
Kostenlose ToolsSafety recalls are issued daily across foods, medications, vehicles, and electronics. Use our instant tools to check your home for active safety warnings:
Übersicht
- Rückrufendes UnternehmenBreckenridge Pharmaceutical, Inc.
- StatusOngoing
- RisikostufeClass II
- DistributionNationwide within the United States
📢 Warnung teilen
Alert family and friends to keep them safe. Copy this quick alert message:
🚨 SAFETY ALERT: Breckenridge Pharmaceutical, Inc. - Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. Check if your household is affected: https://therecallfile.com/de/recalls/duloxetine-delayed-release-capsules-usp-60mg-packaged-in-a-90-capsules/FDA-D-0583-2026
Alarm-Liste abonnieren
Erhalten Sie sofortige E-Mail-Benachrichtigungen bei kritischen Produktrückrufen.
Support The Recall File
Help keep official recall alerts free, accessible, and fast for everyone.